Harmony Biosciences Holdings, Inc. (HRMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and follo ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Regeneron (REGN) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a prove ...

文章核心观点 - UBS 对 Harmony Biosciences Holdings Inc (HRMY) 发起了覆盖,这是一家专注于罕见神经系统疾病的商业阶段生物制药公司 [1] - 公司的上市药物 Wakix (pitolisant) 获批用于成人失眠症患者的过度日间嗜睡或嗜睡发作 [1] - Wakix 在 2024 年第二季度的净收入为 1.72.8 亿美元,同比增长 29% [1] - Wakix 的患者人数环比增加约 250 人,达到约 6,550 人 [1] - UBS 给予 Harmony 买入评级,目标价为 56 美元,认为 Wakix 有望持续增长 [1] 行业分析 公司业务 - Wakix 在嗜睡症市场的地位良好,有望受益于对该疾病认知度的提高,诊断率从目前的约 50% 有上升空间 [2] - Wakix 在多药联合治疗市场也有优势,相比其他已批准药物具有差异化特点 [2] - 公司最近的业务拓展交易可能为管线带来多元化的机会,如收购 Epygenix Therapeutics 获得罕见癫痫药物 Zygel [2] - Zygel 在脆性 X 综合征的III期临床试验有望取得积极结果,预计 2025 年中期公布数据 [2]

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by th ...

PLYMOUTH MEETING, Pa., Aug. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Wells Fargo 2024 Healthcare Conference Location: Boston Fireside Chat: Thursday, September 5, 2024, at 9:30 a.m. ET 2024 Cantor Global Healthcare Conference Location: New York City Fireside Chat: Tuesday, September 17, 2024, at 3:05 p.m. ET A webcast of the fireside chats will be available on th ...

| --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------|-------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | | ...

Harmony Biosciences Holdings, Inc. (HRMY) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company. Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings ...

Mohammed Haneefa Nizamudeen/iStock via Getty Images Today, we are circling back on Harmony Biosciences (NASDAQ:HRMY) for the first time since our last article on this small biopharma name in March 2023. The company has received some more favorable analyst firm coverage recently, and also recently garnered an approval for a label extension. Harmony has made several recent acquisitions to expand its pipeline as well. The company just reported second quarter results. Still, a decent amount of the overall float ...

Harmony Biosciences Holdings, Inc. (HRMY) closed the last trading session at $35.09, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $43.88 indicates a 25.1% upside potential. The average comprises eight short-term price targets ranging from a low of $28 to a high of $56, with a standard deviation of $10.20. While the lowest estimate indicates a decline of 20.2% from t ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision ...